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Abstract: Despite recommendations for annual vaccination against inﬂ  uenza, more than half 
of patients with chronic obstructive pulmonary disease (COPD) in developed countries do not 
receive this vaccine. Inﬂ  uenza is characterized by its potentially of causing epidemics and by 
excess morbidity and mortality in patients with COPD and other chronic medical conditions. 
Good evidence of the efﬁ  cacy, effectiveness, and cost-effectiveness of inﬂ  uenza vaccination 
underlines the recommendation of use in patients with COPD. Inﬂ  uenza vaccination could 
reduce inﬂ  uenza-related complications and exacerbations in patients with COPD, therefore 
reducing hospitalizations and deaths. Each year, all persons with COPD should be vaccinated 
with the inactivated trivalent inﬂ  uenza vaccine containing the most frequent two inﬂ  uenza A 
viral strains and one inﬂ  uenza B viral strain detected in the inﬂ  uenza season of the previous year. 
To achieve a 100% vaccination rate in patients with COPD, all patients with COPD registered 
in health insurance companies and attended in health centers and specialized clinics should be 
vaccinated during the immunization period (October–December). Antiviral therapies could be 
used as an adjunct to vaccination and to reduce inﬂ  uenza transmission in outbreaks. Antiviral 
therapies could reduce the duration and complications of inﬂ  uenza when administered within 
two days of the onset of illness. Research is necessary for new antiviral therapies that could 
prevent inﬂ  uenza with cost-effectiveness similar to the inﬂ  uenza vaccine.
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Introduction
Inﬂ  uenza is an acute respiratory disease that causes epidemics and pandemics in the 
human populations from temperate regions. Inﬂ  uenza epidemics occur every year dur-
ing winter months, affecting 10%–20% of the population (Cox and Subbarao 1999). 
Inﬂ  uenza viruses also can cause pandemics, during which rates of illness and death 
from inﬂ  uenza-related complications increase worldwide. Incidence rates of inﬂ  uenza 
infection vary with the nature of the virus strains and the population affected. Rates 
of serious illness are highest among persons aged 65 years, children aged <2 years, 
and persons with high-risk conditions for inﬂ  uenza-related complications, such as 
chronic obstructive pulmonary disease (COPD) (Barker 1986; Thompson et al 2003; 
Glezen et al 2000). 
Inﬂ  uenza vaccination is the primary method of prevention and control of inﬂ  uenza 
in persons with COPD. It can reduce inﬂ  uenza-related respiratory illness, physician 
visits, hospitalization, and death (OTA 1981; Patriarca et al 1986; Heikkinen et al 1991; 
Mullooly et al 1994; Gross et al 1995; Bridges 2000; Anthonisen 2002). Inﬂ  uenza 
vaccination levels increased during the 1990s, but they are lower than 50% in high-risk 
patients in the US and other developed countries (Harper et al 2005). The objectives of 
this article are to review the evidence supporting the inﬂ  uenza vaccination in patients International Journal of COPD 2007:2(1)  42
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with COPD and to present effective strategies to increase 
vaccination levels in patients with COPD.
Virology, epidemiology, 
and pathophysiology of inﬂ  uenza 
The inﬂ  uenza virus (80–120 nm) is a member of the family 
Orthomyxoviridae, including three serotypes: A, B, and C 
(Cox et al 2000). Inﬂ  uenza A and inﬂ  uenza B are the most 
signiﬁ  cant pathogens in terms of morbidity and mortality. 
Type A is responsible for epidemics. Inﬂ  uenza C rarely 
produces clinical disease and has not been responsible for 
epidemics.
The influenza virus is a negative-strand RNA virus 
with a genome consisting on seven (inﬂ  uenza C) or eight 
(inﬂ  uenza A and B) segments of RNA. Each segment of 
RNA is encapsided by the viral nucleoprotein (NP) and is 
associated with a polymerase complex. The particle consist-
ing of the NP and the RNA polymerase complex is called 
ribonucleoprotein (RNP) particle. The RNP particles are 
enclosed by a protein shell called capside, formed from the 
assembly of helical proteins called matrix protein (M1). The 
capside is surrounded by a lipoprotein envelope derived from 
the plasma membrane of infected cells, which contain two 
types of spikes (8–14 nm). One spike is a box-shaped protein 
called neuraminidase (N) and the other spike is a protein 
called hemagglutinin (H). The lipid envelope contains also 
a tetrameric ion channel protein called M2. 
The influenza virus cycle can be divided into eight 
stages (Figure 1). Infection is initiated with the attachment 
of virions to susceptible host cells by reactions between 
the hemagglutinin particle and speciﬁ  c receptors on the 
respiratory epithelium (White and Wilson 1987) (stage 1). 
Receptor-bound viruses are taken into the cell by endocytosis 
(stage 2). Subviral particles formed by viral ribonucleoprotein 
(RBN) and protein M are released into the cell cytoplasm 
and transported into the nucleus (stage 3). In the cell nucleus, 
new viral RNA is formed by primary transcription (stage 4), 
and replication and secondary transcription of the viral RNA 
(stage 5). Viral proteins are formed by translation of mes-
senger viral RNA (mRNA) by cell’s ribosomes (stage 6) and 
post-translational modiﬁ  cation (stage 7). The same enzyme 
that makes mRNA is responsible for the secondary transcrip-
tion, thus replicating the viral genome. In the nucleus, M1 
proteins bind to newly synthesized (-) strand viral RNAs 
forming RNP particles. New viral particles are formed when 
RNP is encased by the capside and transported to the cell 
surface, where they are released surrounded by a cell-derived 
lipid membrane envelope containing hemagglutinin and 
neuraminidase proteins (stage 8). 
The hemagglutinin is responsible for both virus attach-
ment and RNP release into the cell cytoplasm (White and 
Wilson 1987). The hemagglutinin is the major glycoprotein 
component of the viral envelope. It is homotrimeric and is 
composed of two polypeptide segments, designated HA1 and 
HA2. The HA1 segments form sialic acid-binding sites and 
mediate HA attachment to the host cell surface. The HA2 seg-
ment forms the membrane-spanning anchor, and its amino-
terminal region, which is called fusion peptide, appears to be 
directly involved in the fusion reaction mechanism.
Inﬂ  uenza A viruses are classiﬁ  ed into different subtypes 
based on their surface glycoproteins hemagglutinin (H) and 
neuraminidase (N). Fifteen subtypes of hemagglutinine 
(H1–H15) and nine subtypes of neuraminidase (N1–N9) 
have been identiﬁ  ed. All of these serotypes have been found 
in aquatic birds. Different species of wild birds form the 
primary natural reservoir of the inﬂ  uenza A virus (Webster 
et al 1992). In humans, however, only three hemagglutinin 
proteins (H1, H2, and H3) and two neuraminidase proteins 
(N1 and N2) have been detected in epidemics and pandemics 
since 1900. 
Since the discovery of the inﬂ  uenza virus, new antigenic 
variants of inﬂ  uenza A and B have continually emerged. 
The inﬂ  uenza virus changes continually by means of two 
mechanisms called antigenic drift and antigenic shift (Palese 
and Young 1982; Kilbourne 1987). The antigenic shift is 
responsible for the major antigenic changes registered in 
human inﬂ  uenza A virus. The antigenic shift is produced 
by the reassortment of genetic components from human and 
nonhuman inﬂ  uenza viruses. The antigenic shift produces new 
human inﬂ  uenza viruses with antigenic components from the 
nonhuman viruses. For example, the genetic reassortment 
of the human inﬂ  uenza virus H2N2 and the avian inﬂ  uenza 
virus H3N8 can produce a new human inﬂ  uenza virus H3N2. 
Inﬂ  uenza pandemics are produced by the lack of a speciﬁ  c 
immune response against the new human viruses in the whole 
population of the world. Persons infected by one inﬂ  uenza vi-
rus develop a speciﬁ  c immune response against the HN strain 
that is not able to recognize the new viral strain.
The antigenic drift is responsible for the minor antigenic 
changes registered in the human inﬂ  uenza viruses A and B. 
The antigenic drift is produced by point mutations in the 
genetic material of existing human viruses. Persons infected 
by one inﬂ  uenza virus develop a strain-speciﬁ  c immune 
response that could not be so efﬁ  cient against a slightly dif-
ferent virus, despite belonging to the same HN strain. For this International Journal of COPD 2007:2(1)  43
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reason, people can get ﬂ  u more than once and it is necessary 
to adapt the inﬂ  uenza vaccine to the minor changes detected 
during the inﬂ  uenza season in the inﬂ  uenza viruses.
Inﬂ  uenza occurs worldwide. In temperate climates it 
appears in the winter, but it can occur any time during pan-
demics. In the tropics inﬂ  uenza is endemic. Inﬂ  uenza caused 
by inﬂ  uenza A viruses are more frequent than those caused 
by type B possibly because of the slower rate of antigenic 
variation in inﬂ  uenza B. Inﬂ  uenza has a death-to-case rate 
of 1–2 deaths per 2000 cases (Harper et al 2005).
Inﬂ  uenza viruses are spread from person to person through 
the coughing and sneezing of infected persons. The incubation 
period for inﬂ  uenza is 1 to 4 days, with an average of 2 days. 
Infected individuals are infectious from the day before symp-
toms begin until approximately 5 days after onset of illness.
Primary inﬂ  uenza illness is characterized by the abrupt 
onset of respiratory and constitutional symptoms, including 
fever, headache, severe tiredness, dry cough, sore throat, 
muscle aches, and runny or stuffy nose. Stomach symptoms 
such as nausea, vomiting, and diarrhea can occur, but they are 
more common in children than adults. Fever usually ranges 
between 38ºC and 40ºC. Fever is often higher in children 
than in adults, while it may be absent in the elderly. Inﬂ  uenza 
illness typically resolves after 3 to 5 days, although cough 
and tiredness can persist for more than two weeks. 
Complications of the acute inﬂ  uenza infection include: 
1) primary viral pneumonia; 2) secondary bacterial pneu-
monia; 3) other secondary bacterial infections, including 
bronchitis, sinusitis, and otitis; 4) exacerbation of a COPD; 
and 5) exacerbation of an underlying heart disease.
The characteristic and uniformly observed lesion 
of inﬂ  uenza is necrosis of the cilial epithelium in the upper and 
middle portions of the respiratory tract. Pathological ﬁ  ndings 
of complicated pneumonia are those characteristics of their 
causative agent (Cox and Subbarao 1999). In patients with 
primary inﬂ  uenza pneumonia, the lungs are airless, heavy with 
sanguineous edema, and mottled by subpleural hemorrhages. 
Bilateral interstitial inﬁ  ltrates can be seen on chest radiography, 
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Figure 1 Inﬂ  uenza virus cycle. 
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but inﬂ  uenza virus infection can cause radiological changes 
similar to those of other causes of pneumonia. Primary viral 
pneumonia beguines within 24 hours of the onset of febrile 
illness with a dry cough that later produces bloody sputum 
accompanied by tachypnea, progressive cyanosis, and respira-
tory failure. Patients deteriorate despite antibiotic therapy, and 
pneumonia is associated with a high mortality rate.
Secondary pneumonia is characterized by the appearance 
of a new fever and productive cough during early convales-
cence. Clinical signs of lobar consolidation can be conﬁ  rmed 
by radiology. Streptococcus pneumoniae, Staphylococcus au-
reus, and Haemophilus inﬂ  uenzae are the bacterial pathogens 
most commonly identiﬁ  ed. Patients with secondary bacterial 
pneumonia respond to antibiotic therapy. A combined viral 
and bacterial pneumonia can present with any combination 
of signs and symptoms.
The inﬂ  uenza virus could produce the exacerbations of 
the underlying COPD due to the primary viral infection and 
secondary bacterial infections. Exacerbation of the under-
lying COPD is characterized by increased breathlessness, 
which is often accompanied by wheezing, chest tightness, and 
increased cough and sputum (Connors et al 1996; Anthonisen 
2002). Exacerbation can also be accompanied by nonspeciﬁ  c 
symptoms, including malaise, insomnia, fatigue, depression, 
and confusion. The risk of dying from a COPD depends on 
the development of respiratory acidosis, the presence of sig-
niﬁ  cant comorbidities, and the need for ventilatory support 
(Anthonisen 1989, 2002). 
The epidemiology of inﬂ  uenza has two dominant charac-
teristics: 1) potentiality for causing epidemics and pandemics, 
2) epidemic-associated excess mortality in high-risk persons. 
Epidemics and pandemics depend on the genetic variability 
of inﬂ  uenza viruses and susceptibility of the population. Inﬂ  u-
enza epidemics involve susceptible children and adolescents, 
who spread influenza to adults in their homes and in the 
community. During epidemics, inﬂ  uenza is associated with a 
death-to-case ratio of 30% in patients with high-risk conditions 
(Glezen 1982). In epidemics, a characteristic time relation-
ship exists between peak occurrence of inﬂ  uenza cases and 
deaths. In the inﬂ  uenza pandemic of 1957 in the US, respiratory 
illnesses reached peak 3 weeks before mortality from inﬂ  uenza 
and pneumonia (Kilbourne 1987). This interval represents the 
spread from the young to the high-risk persons and elderly.
Impact of inﬂ  uenza in patients 
with COPD
Inﬂ  uenza can have a profound social impact, ranging from 
an increased demand for medical services to disruption of 
community services and national economy. The impact of 
inﬂ  uenza in patients with COPD can be important due to 
the higher incidence of inﬂ  uenza-related complications in 
patients with COPD (Barker and Mullooly 1980; Glezen 
et al 1987; Izurieta et al 2000; Neuzil, Mellen, et al 2000; 
Neuzil, Wright, et al 2000). 
Inﬂ  uenza is the most common cause of lower respiratory 
tract infections in developed countries. In the US, 48 mil-
lion cases occur each year, being responsible for 3.9 million 
hospitalizations and 36,000 deaths (NCHS 1998; Thomson 
2004). Physician visits and hospitalizations account for the 
majority of US$3 billion in direct costs. Indirect costs due to 
costs related to work have been estimated in US$15 billion 
per year (Harper et al 2005). During inﬂ  uenza epidemics 
from 1979–80 to 2000–1, the estimated overall number of 
inﬂ  uenza-associated hospitalizations ranged from 54,000 
to 400,000 per epidemic period (Simonsen et al 2000). An 
average of 220,000 inﬂ  uenza-related excess hospitalizations 
occurred per year, with 63% of all hospitalizations occurring 
among persons aged >64 years (Thomson 2004). Estimated 
rates for inﬂ  uenza-related cardiopulmonary problems are 
0.4–0.6 per 100,000 in persons aged 0–49 years, 7.5 per 
100,000 in those aged 50–64 years and 98.3 per 100,000 in 
those aged >64 years (Harper et al 2005). 
Inﬂ  uenza is associated with a death-to-case ratio of 
1–2 per 2000 cases. In the US, the number of deaths at-
tributed to inﬂ  uenza-associated cardiopulmonary problems 
increased from 19,000 in the period 1976–90 to 36,000 in 
the period 1990–99 (Thomson et al 2003). This increase can 
be explained by the higher number of inﬂ  uenza infections 
due to the inﬂ  uenza A H3N2 serotype in the period 1990–99 
(CDC 2004). During this period, 90% of detected viruses 
were from the H3N2 serotype, compared with 57% during 
the period 1976–90 (Thompson et al 2003). During epidemics 
the total number of deaths from inﬂ  uenza can be high due 
to the large number of cases. An epidemic affecting 20% of 
the population of the US, Canada, and Europe could result 
in 70,000–140,000 deaths. 
In developed countries, 5% of persons aged 0–15 years 
and 5%–10% of adults aged 15 or more years have chronic 
bronchitis, emphysema, or unremitting asthma, and more 
than 52 million people suffer from COPD around the world 
(Hurd 2000; Pauwels et al 2001). In the US, over 1.5 million 
new cases are diagnosed from bronchitis, emphysema, or 
COPD each year. In 2001, the total number of persons aged 
25 or more years with COPD was 12 million, of whom 2 
million had emphysema, 9.2 million had bronchitis, and 0.9 
million had both emphysema and chronic bronchitis (NHLBI International Journal of COPD 2007:2(1)  45
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2003). A 10%–20% infection rate in patients with COPD 
can therefore generate an important increase in the demand 
for health services. 
In the adult population, hospitalization rates can be 2 to 
30 times higher among high-risk adults (Table 1). Glezen 
and colleagues (1987) determined the frequency of high-
risk of patients hospitalized with acute respiratory disease 
(ARD). The risk for ARD hospitalization was 19.7 per ten 
thousand for persons with high-risk conditions and only 9.3 
for persons without. Chronic pulmonary disorders were the 
most common underlying conditions identiﬁ  ed, and persons 
with pulmonary conditions had the greatest risk for acute 
respiratory disease hospitalization. The highest rate occurred 
among persons older than 65 years of age with pulmonary 
conditions (87.5 per ten thousand), and the rate was 27.5 
for persons 45 to 64 years of age. Cardiac conditions were 
the second most frequent group of underlying disorders of 
patients hospitalized with ARD. Only for persons younger 
than 20 years of age was the risk of ARD hospitalization 
greater for persons with cardiac conditions than for those 
with pulmonary conditions (22.9 and 14.9 per ten thousand, 
respectively). 
Hospitalization rates can be 5 to 22 times higher in chil-
dren who have medical conditions who put them at increase 
risk for inﬂ  uenza-related complications than in healthy indi-
viduals (Table 1). Izurieta and colleagues (2000) studied hos-
pitalization rates for acute respiratory-disease among infants 
and children aged less than 17 years during the period from 
1992 to 1997, and observed that hospitalization rates were 
5–20 times higher among high-risk individuals at Northern 
California Kaiser sites and 4–22 times higher at Group Health 
Cooperative sites (Table 1). Hospitalization rates among 
children aged <2 years at high risk for complications of in-
ﬂ  uenza were 60 and 48 times higher at Northern California 
Kaiser and Group Health Cooperative sites, respectively, 
than among healthy individuals aged 5–17 years.
Deaths from inﬂ  uenza are more common among persons 
of any age with chronic pulmonary disease and other chronic 
conditions (Simonsen et al 1997). Case fatality with inﬂ  uenza 
A epidemics in patients with COPD can be 30% or more, 
while in healthy persons the case-fatality rate can be 1–2 
per 2000 cases. Combined pulmonary and cardiovascular 
disease can increase the risk of death by 800-fold (Barker 
and Mullooly 1982). Reports of 153 laboratory-conﬁ  rmed 
inﬂ  uenza-related pediatric deaths from 40 states during the 
2003–2004 inﬂ  uenza season indicated that 40% were aged 
<2 years and 30% of those aged 2–17 years have an under-
lying medical condition traditionally considered to place a 
person at risk for inﬂ  uenza-related complications (Harper 
et al 2005). 
Inﬂ  uenza vaccination
The primary strategy for reducing the effect of inﬂ  uenza in 
persons with COPD is vaccinating these patients and their 
contacts each year before seasonal increases in inﬂ  uenza virus 
circulation. Inﬂ  uenza vaccination should be recommended 
in patients with COPD for two reasons. Firstly, vaccination 
can reduce the risk of inﬂ  uenza-related complications and 
exacerbations. Secondly, when vaccine and epidemic strains 
are well-matched, a higher vaccination rate can reduce the 
risk for inﬂ  uenza outbreaks due to herd immunity. Inﬂ  uenza 
vaccination is recommended in the following population 
groups (ACP 1996; USPSTF 1996; WHO 2002; Fukuda 
et al 2004; Harper et al 2005; CDC 2006):
•  Persons aged more than 64 years
•  Persons aged <64 years with one or more of the follow-
ing high-risk conditions for inﬂ  uenza-related complica-
tions:
o  Chronic pulmonary disease
o  Chronic heart disease
o  Diabetes
o  Renal dysfunction
o  Hemoglobinopathies
o  Cancer
o  Human immunodeﬁ  ciency virus infection
o  Immunosuppressant treatment
o  Pregnant women beyond ﬁ  rst trimester during  
 inﬂ  uenza season
o  Persons aged 6 months to 18 years treated with  
  aspirin for a long period
o  Children aged 6–23 months
•  Persons who can transmit inﬂ  uenza to high-risk pa-
tients
Two inﬂ  uenza vaccines are available: the inactivated tri-
valent inﬂ  uenza vaccine (TIV), produced by Sanoﬁ  -Pasteur, 
Chiron Corporation, and GlaxoSmithKline, and the live 
attenuated inﬂ  uenza vaccine (LAIV), produced by Med 
Immune Vaccines. Both inactivated inﬂ  uenza vaccine and 
LAIV are available to reduce the risk for inﬂ  uenza infection 
and illness. 
The differences between TIV and LAIV vaccines are pre-
sented on Table 2. Inactivated inﬂ  uenza vaccine contains killed 
viruses, while LAIV contains live, attenuated viruses still capable 
of replication. LAIV is administered by intranasal spray, while 
inactivated inﬂ  uenza vaccine is administered intramuscularly 
by injection. Inactivated inﬂ  uenza vaccine is approved for use International Journal of COPD 2007:2(1)  46
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in healthy and high-risk persons aged 6 months, while LAIV 
is approved for use in healthy persons aged 5–49 years.
Since 1976, inﬂ  uenza vaccines contain one three viral 
strains: inﬂ  uenza A (H3N2) virus, one A (H1N1) virus, and 
one B virus. Recommended composition of the inﬂ  uenza 
vaccine for use in the 2006–07 inﬂ  uenza season include the 
following viral strains: A/New Caledonia/20/99 (H1N1), A/
Wisconsin/67/2005 (H3N2), B/Malaysia/2506/2004 (WHO 
2006). Both vaccines stimulate host response to the antigenic 
determinants on the viral surface. Each year, one or more virus 
strains might be changed on the basis of global surveillance for 
inﬂ  uenza viruses and the emergence and spread of new strains. 
Vaccines should be administered annually to provide optimal 
protection against inﬂ  uenza because inﬂ  uenza antigens change 
progressively with time, so that vaccination against one strain 
could provide little or no protection against new strains. 
Inactivated and live attenuated inﬂ  uenza vaccine should 
not be administered to persons known to have anaphylactic 
hypersensitivity to eggs or to other components of the vac-
cine without ﬁ  rst consulting a physician. Prophylactic use of 
antiviral agents is an option for preventing inﬂ  uenza among 
such persons. Persons who have a history of anaphylactic 
hypersensitivity to vaccine components but who are also at 
high risk for complications from inﬂ  uenza can beneﬁ  t from 
vaccine after appropriate allergy evaluation and desensitiza-
tion. Persons with acute febrile illness usually should not 
be vaccinated until their symptoms have abated. However, 
minor illnesses with or without fever do not contraindicate 
use of inﬂ  uenza vaccine.
The most frequent side effect of inactivated inﬂ  uenza vaccina-
tion is soreness at the injection site that lasts 1–2 days. Immediate 
reactions (eg, hives, angioedema, allergic asthma, and systemic 
anaphylaxis) rarely occur after inﬂ  uenza vaccination. These re-
actions probably result from hypersensitivity to certain vaccine 
components; the majority of reactions probably are caused by 
residual egg protein. Fever, tiredness, muscle aches, and other 
systemic symptoms can occur after vaccination with inacti-
vated vaccine and most often affect persons who have had no 
previous exposure to the inﬂ  uenza virus antigens in the vaccine. 
Local reactions typically are mild and rarely interfere with the 
person’s ability to conduct usual daily activities. One blinded, 
randomized, cross-over study among 1952 adults and children 
with asthma, demonstrated that only body aches were reported 
more frequently after inactivated inﬂ  uenza vaccine (25.1%) 
than placebo-injection (20.8%) (ALAACRC 2001). One study 
reported 20%–28% of children with asthma aged 9 months–18 
years with local pain and swelling (Park et al 1996). Wright 
and colleagues (1977)  reported no difference in local reactions 
among 53 children aged 6 months–6 years with high-risk medi-
cal conditions or among 305 healthy children aged 3–12 years 
in a placebo-controlled trial of inactivated inﬂ  uenza vaccine. In 
a study of 12 children aged 5–32 months, no substantial local or 
systemic reactions were noted (Piedra et al 1993).
The use of a swine inﬂ  uenza inactivated vaccine in 1976 
was associated with an increased frequency of Guillain-Barré 
syndrome (Schonberger et al 1979). The rate of persons 
affected by this medical problem was 1 per 120,000 vac-
cines. Nevertheless, this side-effect has not been observed 
Table 1 Hospitalization rates for acute respiratory disease in patients with and without chronic conditions
      Hospitalizations per   Hospitalizations per
Population  Year of study  Age  100,000 persons with   100,000 persons without
      high-risk conditions  high-risk conditions
HealthMaintenance 1968–1969,  15–44  years  56–110  23–25
Organizations 1970–1971,  45–64  years  392–635  13–23
(Barker et al 1980)  1972–1973  ≥65 years  399–518  -
TennesseeMedicaid 1973–1993  0–11  months 1900  496–1038
(Neuzil et al 2000)    2–4 years  800  196
   5–17  years  320 86
     92  41
Kaiser Permanente  1992–1997  0–1 years  1181  231
(Izurieta et al 2000)    2–4 years  713  53
   5–17  years  386 19
Group Health   1992–1997  0–1 years  772  193 
Cooperative   2–4  years  458  21
(Izurieta et al 2000)    5–17 years  216  16
Population of Houston  1978–1981  All ages  197  93
(Glezen et al 1987)       International Journal of COPD 2007:2(1)  47
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with inﬂ  uenza vaccines administered after 1976 (Kaplan 
et al 1982).
Efﬁ  cacy and effectiveness 
of the inﬂ  uenza vaccine
Efﬁ  cacy and effectiveness of inﬂ  uenza vaccination have been 
demonstrated in children, adults, elderly, and patients with 
high-risk conditions. In health persons the vaccine is 70%–80% 
effective (Harper et al 2005; Fukuda et al 2004; CDC 2006). 
The US Preventive Services Task Force (1996) has strongly 
recommended that clinicians provide inﬂ  uenza vaccina-
tion to patients with COPD, based on the good evidence 
that improved health outcomes and beneﬁ  ts substantially 
outweigh harms.
The vaccine is effective in preventing secondary com-
plications and reducing the risk for inﬂ  uenza-related hospi-
talization and death among adults aged 65 years with and 
without high-risk medical conditions. One study assessing 
vaccine effectiveness in different high-risk subpopulations 
showed that in patients aged more than 64 years with cardio-
pulmonary disease (Nichol et al 1998), inﬂ  uenza vaccination 
reduced inﬂ  uenza-related hospitalizations by 29% and deaths 
from all-cause by 49%. In patients with other chronic condi-
tions such as diabetes, renal disease, rheumatologic disease, 
and stroke, inﬂ  uenza vaccination reduced hospitalizations by 
32% and deaths from all-cause by 64%. In the healthy persons, 
inﬂ  uenza vaccination reduced hospitalizations by 49% and 
deaths from all-cause by 55%. 
Nonrandomized studies in individuals aged >64 years 
with or without chronic medical conditions have reported that 
vaccine reduces pneumonia and inﬂ  uenza hospitalizations by 
18% to 52% and deaths from all causes by 27% to 70% (Gross 
et al 1995; Nichol et al 1998, 1999; Fedson et al 1992; Nordin 
et al 2001). One meta-analysis estimated that inﬂ  uenza vaccine 
reduced inﬂ  uenza-like illness by 33% (95% conﬁ  dence interval 
[CI]: 27%–38%), hospitalizations from pneumonia and inﬂ  uen-
za by 33% (95% CI: 27%–38%), and mortality from all causes 
by 50% (95% CI: 46%–56%) in community-dwelling elderly 
(Vu et al 2002). A second meta-analysis including cohort 
studies in both nursing homes and noninstitutionalized elderly 
population estimated that inﬂ  uenza vaccine reduced respiratory 
illness by 56% (95% CI: 39%–68%), hospitalizations by 
Table 2 Inactivated inﬂ  uenza vaccine compared with live attenuated inﬂ  uenza vaccine
  Inactivated vaccine (TIV)  Live attenuated vaccine(LAIV)
Type of vaccine  Killed virus  Live virus
Route of administration  Intramuscular injection  Intranasal spray
Vaccine strains updated  Annually  Annually
Number of strains included  2 inﬂ  uenza A   2 inﬂ  uenza A
 1  inﬂ  uenza B  1 inﬂ  uenza B
Inﬂ  uenza A strains in 2005 vaccine  California/7/2004 (H3N2)  California/7/2004 (H3N2)
  New Caledonia/20/99 (H1N1)  New Caledonia/20/99 (H1N1)
Inﬂ  uenza B strain in 2005 vaccine  Shanghai/361/2002  Shanghai/361/2002
Approved age  ≥6 months  5–49 years
Approved for persons with chronic 
obstructive pulmonary disease   Yes  No
Approved for other high-risk persons  Yes  No
Can be administered to family members 
or close contacts of high-risk persons 
not severely immunosuppressed  Yes  Yes
Can be administered to family members 
or close contacts of immunosuppressed 
persons not requiring a protected 
environment Yes  Yes
Can be administered to family members 
or close contacts of immunosuppressed 
persons requiring a protected environment  Yes  Inactivated vaccinepreferred
Can be administered simultaneously with 
other vaccines  Yes  Yes
Can be administered within 4 weeks of 
another inactivated vaccines  Yes  Yes
Can be administered within 4 weeks of 
another live vaccines  Yes  Yes, but prudent to space 4 weeks apartInternational Journal of COPD 2007:2(1)  48
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50% (95% CI: 28%–65%), and mortality by 68% (95% CI: 
56%–76%) (Mullooly et al 1994). 
Several case-control studies have shown the effective-
ness of inﬂ  uenza vaccination to prevent hospitalizations. 
One study carried out in the UK estimated that vaccination 
reduced inﬂ  uenza, pneumonia, bronchitis, and emphysema by 
63% (Ahmed et al 1997). Another study carried out in Spain 
showed that vaccination reduced serologically conﬁ  rmed 
pneumonia by 79% (Ohmitt and Monto 1995). 
One major factor inﬂ  uencing on the vaccine effectiveness 
is the antigenic similarity between vaccine viral strains and 
circulating strains (Edwards et al 1994; Nichol et al 1995; 
Grotto et al 1998; Pyhala et al 2001). When vaccine and 
circulating viruses are well matched, vaccine can reduce 
laboratory-conﬁ  rmed inﬂ  uenza illness in adults aged <65 
years by 70%–90% (Demichelei et al 2000), but in one study 
carried out when vaccine and circulating strains were not 
well matched, laboratory-conﬁ  rmed inﬂ  uenza illness was 
reduced by 52% in healthy persons and by 38% in patients 
with high-risk conditions (CDC 2006). In another study in 
persons with high-risk conditions, vaccine effectiveness 
ranged from 43% to 56% when antigens from vaccine and 
circulating strains were similar and from 21% to 42% when 
they were not well matched (Nichol et al 1998).
In working population, inﬂ  uenza vaccination can reduce 
upper respiratory illness by 25%, laboratory-conﬁ  rmed inﬂ  u-
enza illness by 86%–88% and febrile respiratory illness by 
29%–34%. Physician visits and illness-related work absentee-
ism can be reduced by 42% and 32%–52%, respectively (Patri-
arca et al 1986; Mullooly et al 1994; Demicheli et al 2000).
Children aged 6 months can develop protective levels 
of anti-inﬂ  uenza antibody against speciﬁ  c inﬂ  uenza virus 
strains after inﬂ  uenza vaccination. One study in children with 
asthma aged 2–6 years and 7–14 years obtained a vaccine 
efﬁ  cacy of 22%–54% and 60%–78%, respectively (Sugaya 
et al 1994). A 2-year randomized study of children aged 6–24 
months determined that 89% of children seroconverted to 
all three vaccine strains during both years (Hoberman et al 
2003). Other studies report that inactivated TIV decreases the 
incidence of inﬂ  uenza-associated otitis media among young 
children by approximately 30% (Heikkinen et al 1991; Cle-
ments et al 1995).
Cost-effectiveness of inﬂ  uenza 
vaccine
All evaluative studies assessing the cost-effectiveness of 
inﬂ  uenza vaccination obtained favorable cost-effectiveness 
ratios or cost savings (Nichol et al 2003; Rothberg 2005). 
In one 6-year study of elderly, members of a managed care 
organization obtained a net cost saving of US$73 per vacci-
nated person (Nichol et al 1998). An evaluative study carried 
out in The Netherlands obtained a cost-effectiveness ratio of 
€1820 per life year gained in elderly persons and cost savings in 
chronically ill elderly persons (Postma et al 1999). In one study 
assessing the cost quality adjusted life year gained (QALY) 
that included all age groups, cost savings were obtained in 
persons aged 65 years, while in younger individuals the 
cost-effectiveness ratio ranged from US$23 to US$256 per 
QALY (Bridges et al 2000). Cost-effectiveness of inﬂ  uenza 
vaccination is lower in healthy individuals aged <64 years 
because healthcare costs from inﬂ  uenza are lower in younger 
individuals.
Inﬂ  uenza vaccination can reduce healthcare costs with 
inﬂ  uenza illness. Economic studies of inﬂ  uenza vaccination 
of persons aged 65 years conducted in the US have reported 
overall societal cost savings and substantial reductions in 
hospitalization and death (Harper et al 2005). Studies of 
adults aged <65 years have reported that vaccination can 
reduce both direct medical costs and indirect costs from work 
absenteeism (Patriarca et al 1986; Mullooly et al 1994; Gross 
et al 1995; Bridges et al 2000; Nichol 2001). Reductions of 
13%–44% in healthcare provider visits, 18%–45% in lost 
workdays, 18%–28% in days working with reduced effec-
tiveness, and 25% in antibiotic use for inﬂ  uenza-associated 
illnesses have been reported (Patriarca et al 1986; Mullooly 
et al 1994; Demicheli et al 2000; Nichol et al 2003, 2004). 
The cost-effectiveness of inﬂ  uenza vaccination depends 
on the following factors: 1) efﬁ  cacy and effectiveness of the 
vaccine, 2) incidence of inﬂ  uenza, 3) vaccination costs, and 
4) healthcare costs from inﬂ  uenza. A higher inﬂ  uenza vaccine 
efﬁ  cacy and effectiveness is associated with a higher reduction 
in healthcare costs and a higher cost-effectiveness. For this 
reason, in evaluative studies taking into account results obtained 
in clinical trails and cohort studies, the cost-effectiveness is 
higher when vaccine and circulating viral strains are well 
matched. Vaccine-related reduction in healthcare costs 
from inﬂ  uenza is higher when attack rate and healthcare 
costs per case are higher. One cost-effectiveness analysis 
estimated a cost of US$60 to US$4000 per illness averted 
among healthy persons aged 18–64 years, depending on 
inﬂ  uenza attack rates and vaccine effectiveness (Demicheli 
et al 2000). Cost-effectiveness of inﬂ  uenza vaccination 
depends also on vaccination costs. In one evaluative study 
assessing the cost-effectiveness of vaccinating elderly people 
in a low cost vaccination centre, a net cost saving of US$117 
per individual was obtained (Nichol et al 1998). International Journal of COPD 2007:2(1)  49
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Antiviral treatment 
and chemoprophylaxis
Although inﬂ  uenza vaccination is the cornerstone for the 
control and treatment of inﬂ  uenza, antiviral medications can 
be used as an adjunct to vaccination. Four antiviral drugs are 
available for the prevention and treatment of inﬂ  uenza infec-
tions (Table 3). Oseltamivir and zanamivir are neuraminidase 
inhibitors, acting against both inﬂ  uenza A and B infections. 
Rimantadine and amantadine block the M2 channel of inﬂ  u-
enza A virus. Dosage recommendations vary by age group 
and medical conditions (Table 3).
When administered within two days of illness onset to 
healthy adults, amantadine and rimantadine can reduce the 
duration of uncomplicated inﬂ  uenza A illness, and zanamivir 
and oseltamivir can reduce the duration of uncomplicated 
inﬂ  uenza A and B illness by approximately 1 day, compared 
with placebo (Harper et al 2005). Antiviral therapies could 
possibly reduce inﬂ  uenza duration and complications in 
patients with COPD and other medical conditions, although 
information concerning the effectiveness of amantadine, 
rimantadine, zanamivir, and oseltamivir in patients with 
chronic medical conditions are limited (Hayden et al 1997; 
Cooper et al 2003; Jefferson et al 2000).
Resistance against rimantadine and amantadine can ap-
pear rapidly in approximately one third of patients receiving 
these therapies (Hayden et al 1992; Saito et al 2002). During 
the course of amantadine or rimantadine therapy, resistant 
inﬂ  uenza strains can replace susceptible strains within 2–3 
days of starting therapy. Resistant viruses have been isolated 
from persons who live at home or in an institution where 
other residents are taking or have recently taken amantadine 
or rimantadine as therapy. Amantadine- and rimantadine-
resistant viruses are not more virulent or transmissible than 
susceptible viruses (Hayden et al 1992). The screening of 
epidemic strains of inﬂ  uenza A has rarely detected amanta-
dine- and rimantadine-resistant viruses (Ziegler et al 1999). 
Development of viral resistance to zanamivir and oseltamivir 
during treatment has been identiﬁ  ed but does not appear to 
be frequent (Jackson et al 2000). To reduce the emergence 
of antiviral drug-resistant viruses, amantadine or rimantadine 
therapy for persons with inﬂ  uenza A illness should be discon-
tinued as soon as clinically warranted, typically after 3–5 days 
of treatment or within 24–48 hours after the disappearance of 
signs and symptoms. The recommended duration of treatment 
with either zanamivir or oseltamivir is 5 days.
Chemoprophylactic drugs can be used as adjuncts to vac-
cination in preventing and controlling inﬂ  uenza. Both aman-
tadine and rimantadine are indicated for chemoprophylaxis 
of inﬂ  uenza A infection, but not inﬂ  uenza B (Table 3). Both 
drugs are approximately 60%–90% effective in preventing 
illness from inﬂ  uenza A infection (Wintermeyer and Nahata 
1995; Demicheli et al 2000). Amantadine and rimantadine 
have been studied extensively among nursing home popula-
tions as a component of inﬂ  uenza outbreak-control programs, 
which can limit the spread of inﬂ  uenza within chronic-care 
institutions (Guay 1994; Wintermeyer and Nahata 1995). 
Antiviral therapy can be used to prevent inﬂ  uenza in 
patients with COPD and other chronic conditions in the fol-
lowing situations:
1)  When they have not been vaccinated.
2) When  inﬂ  uenza vaccine has a lower efﬁ  cacy and effec-
tiveness due to viral antigenic variation. 
3) When  inﬂ  uenza vaccine is contraindicated. 
4)  When they are known to have experienced Guillain-Barré 
syndrome within 6 weeks after a previous inﬂ  uenza vac-
cination. 
Table 3 Comparison of antiviral drugs for the treatment and prophylaxis of inﬂ  uenza
    Dosage in individuals   Effective     Precautions in patients with:
    aged >12 years   against        Hepatic 
Drug Indication    inﬂ  uenza   Side effects %  COPD  Renal problems  problems
Amantadine  Treatment  100 mg bid*  A  0–70  No  Yes  Yes
  Prophylaxis  100 mg bid*
Rimantadine  Treatment  100 mg bid*  A  0–2  No  Yes  Yes
  Prophylaxis  100 mg bid*
Oseltamivir  Treatment  75 mg bid  A and B  5–10  No  Yes  No
 Prophylaxis  75  mg/day
Zanamivir  Treatment  10 mg bid   A and B  <1  Yes  No  No
 Prophylaxis  not  approved
Abbreviations: bid, twice per day; COPD, chronic obstructive pulmonary disease.
Notes: *100 mg/day in the elderly.International Journal of COPD 2007:2(1)  50
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Antiviral therapy can be used also in unvaccinated 
persons who can transmit inﬂ  uenza to high-risk patients, 
including healthcare workers, residents of nursing homes or 
chronic care facilities, close contacts of high-risk patients, 
and household member of high-risk persons.
Antiviral therapy can be used as an adjunct to vaccination 
in controlling outbreaks of inﬂ  uenza among patients with 
COPD and other high-risk conditions in long-term facilities 
and hospitals. The majority of published reports showing 
the efﬁ  cacy and effectiveness of antiviral agents to control 
inﬂ  uenza outbreaks are based, however, on studies carried 
out in nursing homes where amantadine and rimantadine 
were used to prevent influenza A infections (Patriarca 
et al 1987; Guay 1994; Wintermeyer and Nahata 1995). The 
prophylactic use of zanamivir and oseltamivir in nursing 
homes and among patients with chronic medical conditions 
is more limited, but their efﬁ  cacy and effectiveness could be 
similar to that for amantadates (Bowles et al 2002; Schilling 
et al 1998; Lee et al 2000; Parker et al 2001).
Persons at high risk for complications of inﬂ  uenza still 
can be vaccinated after an outbreak of inﬂ  uenza has begun in 
a community. Medication should be taken, in this situation, 
for two weeks in order to provide early protection until 
vaccine-induced antibodies appear. When inﬂ  uenza vaccine 
is administered while influenza viruses are circulating, 
chemoprophylaxis should be considered for persons at high risk 
during the time from vaccination until immunity has developed. 
Children aged <9 years who receive inﬂ  uenza vaccine for the 
ﬁ  rst time can require six weeks of prophylaxis (ie, prophylaxis 
for four weeks after the ﬁ  rst dose of vaccine and an additional 
two weeks of prophylaxis after the second dose). 
When determining the timing and duration for administer-
ing inﬂ  uenza antiviral medications for prophylaxis, factors 
related to cost, compliance, and potential side effects should be 
considered. To be maximally effective as prophylaxis, the drug 
must be taken each day for the duration of inﬂ  uenza activity in 
the community. However, to be most cost-effective, one study 
of amantadine or rimantadine prophylaxis reported that the 
drugs should be taken only during the period of peak inﬂ  uenza 
activity in a community (Patriarca et al 1987).
When outbreaks occur in institutions, chemoprophylaxis 
should be administered to all residents, regardless of whether 
they received inﬂ  uenza vaccinations during the previous fall 
and should continue for a minimum of two weeks. If surveil-
lance indicates that new cases continue to occur, chemopro-
phylaxis should be continued until approximately one week 
after the end of the outbreak. The dosage for each resident 
should be determined individually. Chemoprophylaxis can 
be offered to the unvaccinated staff providing healthcare to 
persons at high risk. Prophylaxis should be considered for 
all employees, regardless of their vaccination status, if the 
outbreak is caused by a variant strain of inﬂ  uenza that is not 
well-matched by the vaccine. 
To limit the potential transmission of drug-resistant 
virus during outbreaks in institutions, whether in chronic or 
acute-care settings or other closed settings, measures should 
be taken to reduce contact as much as possible between per-
sons taking antiviral drugs for treatment and other persons, 
including those taking chemoprophylaxis, and therapy with 
amantadine and rimantadine for persons with inﬂ  uenza A ill-
ness should be discontinued as soon as clinically warranted, 
typically after 3–5 days of treatment or within 24–48 hours 
after the disappearance of signs and symptoms.
Vaccination strategies in patients 
with COPD
Successful vaccination programs in persons with COPD 
should combine a plan for identifying persons with COPD, 
use of reminder/recall systems, assessment of practice-level 
vaccination rates with feedback to staff, and efforts to remove 
administrative and ﬁ  nancial barriers that prevent persons 
from receiving the vaccine (Lawson et al 2000). All patients 
with COPD should be vaccinated each year with the best 
available inﬂ  uenza vaccine, and monitoring inﬂ  uenza disease 
and inﬂ  uenza vaccine efﬁ  cacy. The following strategies could 
be developed to achieve higher vaccination levels:
1)  Vaccinating patients with COPD in different healthcare 
facilities during the immunization period (October to 
December in the Northern hemisphere and April to June 
in the Southern hemisphere). 
2) Developing specific influenza vaccination programs 
in primary healthcare centers and outpatient facilities 
attending patients with COPD.
The immunization period begins in October (Northern 
hemisphere). October and November is the best time to get 
vaccinated, but receiving vaccination in December or later 
can still be beneﬁ  cial. The ﬂ  u season can begin as early as 
October and last as late as May. The ﬁ  rst vaccination strategy 
can be developed in different healthcare settings, including 
1) outpatient facilities providing ongoing care, 2) outpatient 
facilities providing episodic or acute care, 3) nursing homes 
and other residential long-term care facilities, 4) acute-care 
hospitals, 5) visiting nurses and other providing home care to 
patients with COPD, and 6) workplace healthcare facilities.
Hospitals are important sites for immunization because 
persons at increased risk for subsequent hospitalization can International Journal of COPD 2007:2(1)  51
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easily be identiﬁ  ed and vaccinated. In fact, each year, a 
percentage of patients hospitalized for inﬂ  uenza had been 
discharged during the immunization period. In one study, 
39%–46% of adult patients hospitalized during the winter 
with inﬂ  uenza-related diagnoses had been hospitalized during 
the preceding autumn (Fedson et al 1992). The CDC (2006) 
recommends that persons of all ages with high-risk conditions 
who are hospitalized at any time during September–March 
should be offered and strongly encouraged to receive inﬂ  uenza 
vaccine before they are discharged. The Global Initiative for 
COPD considers that inﬂ  uenza vaccination should be given to 
patients with COPD in hospitals to prevent future exacerbations 
(Pauwels et al 2001). Thus, the hospital serves as a setting in 
which the Advisory Committee on immunization Practices 
(ACIP) of the United States recommends that vaccine pro-
viders focus their vaccination efforts in October and earlier 
primarily on persons aged 50 years, persons aged <50 
years at increased risk for inﬂ  uenza-related complications 
(including children aged 6–23 months), household contacts 
of persons at high risk (including out-of-home caregivers 
and household contacts of children aged 0–23 months), and 
healthcare workers. Vaccination of children aged <9 years 
who are receiving vaccine for the ﬁ  rst time should also begin 
in October or earlier because those persons need a booster 
dose 1 month after the initial dose. Efforts to vaccinate other 
persons who wish to decrease their risk for inﬂ  uenza infection 
should begin in November. 
The second vaccination strategy is based on the use 
of reminder/recall systems to recommend and vaccinate all 
patients with COPD attended in primary healthcare centers and 
outpatient clinics. This strategy is therefore deﬁ  ned as a target-
based strategy (ACP 1996). In this strategy, physicians respon-
sible for patients with COPD view them as a target population for 
whom inﬂ  uenza vaccination should be provided each year: This 
vaccination strategy can be divide into the following steps:
1)  Enumerate patients attending the healthcare facility by 
name, address, age, and principal diagnosis.
2)  Identify patients with COPD. 
3)  Develop a recall system to immunize all patients with 
COPD, and not only those who have a medical visit 
scheduled during the immunization period.
4)  Evaluate vaccination coverage each week, dividing the 
cumulative number of vaccinated patients by the target 
population.
Staff in facilities providing ongoing medical care to 
persons with COPD should identify and label the medical 
records of patients who should receive vaccination. Vaccine 
should be offered during visits beginning in September and 
throughout the inﬂ  uenza season. Persons and institutions 
planning substantial organized vaccination campaigns 
should consider scheduling these events after mid-October 
because the availability of vaccine in any location cannot be 
ensured consistently in early autumn. Scheduling campaigns 
after mid-October will minimize the need for cancellations 
because vaccine is unavailable. Campaigns conducted before 
November using inactivated vaccine should focus efforts 
on vaccination of persons aged 50 years, persons aged 
<50 years at increased risk for inﬂ  uenza-related complica-
tions (including children aged 6–23 months and pregnant 
women), healthcare workers, and household contacts of 
persons at high-risk (including children aged 0–23 months) 
to the extent feasible.
During October and November each year, vaccination 
should be routinely provided to all residents of chronic-care 
facilities with the concurrence of attending physicians. Con-
sent for vaccination should be obtained from the resident or 
a family member at the time of admission to the facility or 
anytime afterwards. All residents should be vaccinated at one 
time, preceding inﬂ  uenza season. Residents admitted through 
March after completion of the vaccination program at the 
facility should be vaccinated at the time of admission. 
Using standing orders programs is recommended for 
long-term-care facilities, hospitals, and home health agen-
cies to ensure the administration of inﬂ  uenza vaccines for 
adults (CMMS 2002). Standing orders programs for inﬂ  uenza 
vaccination should be conducted under the supervision of a 
licensed practitioner according to a physician-approved facil-
ity or agency policy by healthcare workers trained to screen 
patients for contraindications to vaccination, administer vac-
cine, and monitor for adverse events. In the US, the Centers 
for Medicare and Medicaid Services (CMMS) has removed 
the physician signature requirement for the administration 
of inﬂ  uenza vaccines to Medicare and Medicaid patients in 
hospitals, long-term-care facilities, and home health agen-
cies (CMMS 2002). 
Conclusion
Despite recommendations for annual vaccination against 
inﬂ  uenza in developed countries, more than half of patients 
with COPD and other chronic medical conditions do not 
receive a vaccine. In patients with COPD, influenza is 
associated with complications, such as bacterial pneumonia, 
and worsening of pulmonary disease. Each year, all persons 
with COPD should be vaccinated with the inactivated TIV, 
containing the most frequent two inﬂ  uenza A viral strains and 
one inﬂ  uenza B viral strain detected in the previous inﬂ  uenza International Journal of COPD 2007:2(1)  52
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season. To achieve a 100% vaccination rate in patients with 
COPD, all patients with COPD registered in health insurance 
companies and attended in health centers and specialized 
clinics should be vaccinated during the immunization period 
(October–December in Northern hemisphere and April–May 
in Southern hemisphere). Antiviral therapies could be used 
as an adjunct to vaccination, since they could reduce the 
duration and complications of inﬂ  uenza when administered 
within two days of illness onset. Research is necessary for 
new antiviral therapies that could prevent inﬂ  uenza with 
cost-effectiveness similar to the inﬂ  uenza vaccine.
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